XETRA:DEZ 14 January 2026

March 16, 2026, 4:28 PM EDT. Mineralys Therapeutics, a biopharmaceutical firm targeting hypertension and related conditions, granted inducement stock options and restricted stock units to a new non-executive employee. The Compensation Committee awarded 27,920 stock options and 20,940 restricted stock units under its 2025 Employment Inducement Incentive Award Plan. Options will vest monthly over four years, starting March 16, 2026, with 25% vesting after the first year. Restricted stock units vest similarly over four years with annual 25% increments. The grants comply with Nasdaq Listing Rule 5635(c)(4), permitting stock awards as incentives for new hires. Mineralys develops lorundrostat, a selective aldosterone synthase inhibitor aimed at treating hypertension and comorbidities like chronic kidney disease and obstructive sleep apnea.